CytomX Therapeutics (CTMX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$143.6 million.
- CytomX Therapeutics' Enterprise Value fell 2214.34% to -$143.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.6 million, marking a year-over-year decrease of 2214.34%. This contributed to the annual value of -$100.6 million for FY2024, which is 4233.94% up from last year.
- CytomX Therapeutics' Enterprise Value amounted to -$143.6 million in Q3 2025, which was down 2214.34% from -$158.1 million recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Enterprise Value peaked at -$79.9 million during Q1 2025, and registered a low of -$393.8 million during Q1 2021.
- In the last 5 years, CytomX Therapeutics' Enterprise Value had a median value of -$193.6 million in 2022 and averaged -$195.9 million.
- As far as peak fluctuations go, CytomX Therapeutics' Enterprise Value plummeted by 5883.87% in 2021, and later skyrocketed by 4684.33% in 2025.
- Quarter analysis of 5 years shows CytomX Therapeutics' Enterprise Value stood at -$305.2 million in 2021, then soared by 36.56% to -$193.6 million in 2022, then rose by 9.88% to -$174.5 million in 2023, then soared by 42.34% to -$100.6 million in 2024, then plummeted by 42.74% to -$143.6 million in 2025.
- Its last three reported values are -$143.6 million in Q3 2025, -$158.1 million for Q2 2025, and -$79.9 million during Q1 2025.